Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Frances A Shepherd

Showing results (71-80 of 384) with videos related to

Pageof 39
Sort By:
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 6, 2007
Does intensive follow-up alter outcome in patients with advanced lung cancer?Rachel Benamore, Frances A Shepherd, Natasha Leighl, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 2002
Economic analysis of the TAX 317 trial: docetaxel versus best supportive care as second-line therapy of advanced non-small-cell lung cancerNatasha B Leighl, Frances A Shepherd, Rita Kwong, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 2005
Influence of sex on toxicity and treatment outcome in small-cell lung cancerSimron Singh, Wendy Parulekar, Nevin Murray, et al.
JAMA Network Open|August 31, 2023
SARS-CoV-2 Infection, Hospitalization, and Mortality in Adults With and Without CancerSeyed M Hosseini-Moghaddam, Frances A Shepherd, Sarah Swayze, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 23, 2015
Inhibiting MDM2-p53 Interaction Suppresses Tumor Growth in Patient-Derived Non-Small Cell Lung Cancer Xenograft ModelsJosephine Hai, Shingo Sakashita, Ghassan Allo, et al.
Scientific Reports|January 7, 2017
TRIM14 is a Putative Tumor Suppressor and Regulator of Innate Immune Response in Non-Small Cell Lung CancerJosephine Hai, Chang-Qi Zhu, Tao Wang, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 21, 2015
PTPRF Expression as a Potential Prognostic/Predictive Marker for Treatment with Erlotinib in Non-Small-Cell Lung CancerDenis Soulières, Fred R Hirsch, Frances A Shepherd, et al.
Clinical Lung Cancer|June 28, 2006
Smoking history and epidermal growth factor receptor expression as predictors of survival benefit from erlotinib for patients with non-small-cell lung cancer in the National Cancer Institute of Canada Clinical Trials Group study BR.21Gary M Clark, Denni M Zborowski, Pedro Santabarbara, et al.
Seminars in Oncology|February 1, 2017
Docetaxel (Taxotere) shows survival and quality-of-life benefits in the second-line treatment of non-small cell lung cancer: A review of two phase III trialsFrances A Shepherd, Frank V Fossella, Thomas Lynch, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 11, 2003
Expression and prognostic significance of kit, protein kinase B, and mitogen-activated protein kinase in patients with small cell lung cancerFiona H Blackhall, Melania Pintilie, Michael Michael, et al.
Pageof 39

Showing results (71-80 of 384) with videos related to

Sort By:
Pageof 39
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 6, 2007
Does intensive follow-up alter outcome in patients with advanced lung cancer?Rachel Benamore, Frances A Shepherd, Natasha Leighl, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 2002
Economic analysis of the TAX 317 trial: docetaxel versus best supportive care as second-line therapy of advanced non-small-cell lung cancerNatasha B Leighl, Frances A Shepherd, Rita Kwong, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 2005
Influence of sex on toxicity and treatment outcome in small-cell lung cancerSimron Singh, Wendy Parulekar, Nevin Murray, et al.
JAMA Network Open|August 31, 2023
SARS-CoV-2 Infection, Hospitalization, and Mortality in Adults With and Without CancerSeyed M Hosseini-Moghaddam, Frances A Shepherd, Sarah Swayze, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 23, 2015
Inhibiting MDM2-p53 Interaction Suppresses Tumor Growth in Patient-Derived Non-Small Cell Lung Cancer Xenograft ModelsJosephine Hai, Shingo Sakashita, Ghassan Allo, et al.
Scientific Reports|January 7, 2017
TRIM14 is a Putative Tumor Suppressor and Regulator of Innate Immune Response in Non-Small Cell Lung CancerJosephine Hai, Chang-Qi Zhu, Tao Wang, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 21, 2015
PTPRF Expression as a Potential Prognostic/Predictive Marker for Treatment with Erlotinib in Non-Small-Cell Lung CancerDenis Soulières, Fred R Hirsch, Frances A Shepherd, et al.
Clinical Lung Cancer|June 28, 2006
Smoking history and epidermal growth factor receptor expression as predictors of survival benefit from erlotinib for patients with non-small-cell lung cancer in the National Cancer Institute of Canada Clinical Trials Group study BR.21Gary M Clark, Denni M Zborowski, Pedro Santabarbara, et al.
Seminars in Oncology|February 1, 2017
Docetaxel (Taxotere) shows survival and quality-of-life benefits in the second-line treatment of non-small cell lung cancer: A review of two phase III trialsFrances A Shepherd, Frank V Fossella, Thomas Lynch, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 11, 2003
Expression and prognostic significance of kit, protein kinase B, and mitogen-activated protein kinase in patients with small cell lung cancerFiona H Blackhall, Melania Pintilie, Michael Michael, et al.
Pageof 39